In experimental settings, CB1 agonists like THC do alter sleep architecture, shifting NREM and REM balance and restructuring intermediate sleep stages.
Verisk Analytics' recent slump aligns with an industry-wide downturn, as evidenced by similar trends in Moody's and Experian.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results